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Abstract
Introduction
This study investigated the degree and direction (kHR) of the heart rate to performance
curve (HRPC) during cardio-pulmonary exercise (CPX) testing and explored the relationship
with diabetes markers, anthropometry and exercise physiological markers in type 1 diabetes
(T1DM).
Material and methods
Sixty-four people with T1DM (13 females; age: 34 ± 8 years; HbA1c: 7.8 ± 1% (62 ± 13
mmol.mol-1) performed a CPX test until maximum exhaustion. kHR was calculated by a sec-
ond-degree polynomial representation between post-warm up and maximum power output.
Adjusted stepwise linear regression analysis was performed to investigate kHR and its asso-
ciations. Receiver operating characteristic (ROC) curve was performed based on kHR for
groups kHR < 0.20 vs. > 0.20 in relation to HbA1c.
Results
We found significant relationships between kHR and HbA1c (β = -0.70, P < 0.0001), age
(β = -0.23, P = 0.03) and duration of diabetes (β = 0.20, P = 0.04). Stepwise linear regression
resulted in an overall adjusted R2 of 0.57 (R = 0.79, P < 0.0001). Our data revealed also sig-
nificant associations between kHR and percentage of heart rate at heart rate turn point from
maximum heart rate (β = 0.43, P < 0.0001) and maximum power output relativized to body-
weight (β = 0.44, P = 0.001) (overall adjusted R2 of 0.44 (R = 0.53, P < 0.0001)). ROC curve
analysis based on kHR resulted in a HbA1c threshold of 7.9% (62 mmol.mol-1).
Conclusion
Our data demonstrate atypical HRPC during CPX testing that were mainly related to glyce-
mic control in people with T1DM.
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Introduction
Cardio-pulmonary exercise (CPX) testing provides detailed diagnostic information about car-
dio-pulmonary, vascular and musculoskeletal adaptations to physical stressors [1]. Aerobic
performance markers, like thresholds (e.g. ventilatory thresholds or the heart rate turn point
(HRTP)) are recommended to accurately prescribe individualized exercise intensity [2]. These
thresholds relativized to maximum oxygen consumption (VO2max) serve as sensitive markers
to analyze effects of exercise training in both healthy individuals and patients [3]. As an exam-
ple the HRTP, which is based on findings from Conconi and colleagues, was significantly
associated with the second lactate threshold [4–7]. This heart rate (HR) derived threshold is
defined as the intersection of two regression lines of the HR to performance curve (HRPC)
between early stages of CPX testing (peri-first lactate turn point (LTP1)) and maximum power
output (Pmax), determined from a second-degree polynomial representation satisfying the con-
dition of least error squares (Fig 1) [8].
From a physiological point of view the main cause for the HRTP can be seen in the β1-
receptor sensitivity to the catecholamine response [9]. Hofmann et al. investigated the
response to a single dose of the β1-selective antagonist bisoprolol in healthy individuals [10].
This study revealed a significant association between the response to the antagonist and differ-
ent patterns of the HRPC. A regular HRPC translated to inverted HRPC when using the β1-
antagonist. However, an inverted HRPC under placebo did not change its pattern under a β1-
antagonist application. This shows that the inverted HRPC in placebo conditions is caused by
a reduced β1-receptor sensitivity.
Inter-individual differences in HRPC were observed in healthy individuals and in different
groups of patients [8]. In the general population, approximately 86% of people show regular
deflections of HRPC across a sub-maximal (HRTP) to maximal (Pmax) continuum; however,
8% reveal inverted deflections and 6% display linear increases in HRPC.
Chronotropic incompetence (CI) is the inability of the HR to increase in proportion to
raised metabolic demand, and is found mainly in people with coronary artery disease. CI is a
strong and independent predictor of overall mortality [11]. Interestingly, this non-physiologi-
cal cardiac response was also reported in people with type 2 diabetes, where its origin is not
Fig 1. Schematic of the heart rate to performance curve (HRPC) and detection of the heart rate turn point (HRTP) during CPX testing,
illustrating a regular HRPC (A) and an inverted HRPC (B). The difference in HRPC translates to a lower heart rate at HRTP (HRHRTP)
when given as percentage of the maximum heart rate (%HRmax) (difference 10%). kHR = degree and direction of the heart rate to performance
curve. HRmax = maximum heart rate.
https://doi.org/10.1371/journal.pone.0194750.g001
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fully understood. Diabetes per se and/or disease-related comorbidities as well as physiological
anomalies seem to play a role for CI [12].
Poor glycemic control in people with T1DM may be associated with blunted functional
capacity compared to healthy individuals, which is mainly assessed by means of VO2max [13–
15]. Some studies suggested that poor glycemic control may alter cardio-respiratory and meta-
bolic responses to exercise, which translates to a general lower functional capacity in people
with T1DM [13,15]. Furthermore, it has been shown that people with T1DM have a reduced
maximum HR (HRmax) in comparison to their healthy counterparts [13]. Intriguingly, the
blunted effect of HRmax was shown to be dependent on glycemic control [16].
It is currently not known if the degree and the direction (kHR) of the HRPC during CPX
testing is related to glycemic control in people with T1DM. Therefore, the aim of this study
was to investigate kHR during CPX testing and explore relationships to diabetes markers,
anthropometry and exercise physiological markers in a large group of people with T1DM.
Material and methods
Participant characteristics
For this study sixty-four people with T1DM were recruited from October 2012 until March
2013 by advertisement in local newspapers (Table 1, Fig 2):
Consent procedure
Participants gave their written informed consent before any trial related activities. The trial
was performed accordingly to the Declaration of Helsinki (DoH) and Good Clinical Practice
(GCP) Guidelines. The primary study protocol was approved by the local ethics committee
Table 1. Participant characteristics given as mean ± SD and percentage (%).
Characteristic Total (n = 64)
Age (years) 34 ± 8
Female (n; %) 13 (20)
Male (n; %) 51 (80)
Body mass index (kg/m2) 24 ± 2
Duration of diabetes (years) 17 ± 9
HbA1c (% (mmol.mol
-1)) 7.8 ± 1 (62 ± 13)
Total daily dose of insulin (U) 51 ± 15
Multiple daily injections (n; %) 47 (78)
Insulin pump therapy (n; %) 17 (22)
Arterial hypertension 6
Hypothyroidism 5
Hypercholesterolemia 2
Hashimoto thyroiditis 1
ACE inhibitor 6
Levothyroxine 6
Statin 2
Diuretic medication 1
Calcium channel blocker 1
Physical activity (MET min.wk 1)) 3086 ± 2736
Maximum oxygen uptake (ml.kg-1.min-1) 37 ± 5
https://doi.org/10.1371/journal.pone.0194750.t001
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and health authority board. The study protocol was registered with the universal clinical trial
registry, number NCT01704417 [17].
Study procedures
Participants filled in the International Physical Activity Questionnaire (IPAQ) to assess physi-
cal activity (MET min/week). Medical history, medications and patients’ characteristics were
documented on the day of the CPX testing. Immediately afterwards, HbA1c was measured
from a venous blood sample (Automated Glycohemoglobin Analyzer HLC-723G8, Tosoh
Europe N.V, Belgium). Venous blood was collected immediately before and after CPX testing
Fig 2. Consort flow diagram.
https://doi.org/10.1371/journal.pone.0194750.g002
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to evaluate blood glucose concentration (Super GL Glucose Analyzer, Dr. Mu¨ller Gera¨tebau
GmbH, Germany). Participants performed a CPX test until maximum volitional exhaustion
on a cycle ergometer (Ergospirometer PowerCube1-Ergo, Ganshorn Medizin Electronic,
GER) under medical supervision. Participants sat for 3 min (0 watt (W)) on the cycle ergome-
ter before they started the warm-up period of 3 min cycling at an exercise intensity of 30 W for
females and 40 W for males. After the warm-up period, the intensity was increased by 30 W
for females and 40 W for males every 3 minutes until maximum volitional exhaustion. Finally,
an active recovery period was conducted for 1 min.
Measurements
Pulmonary gas exchange variables were measured continuously. Data were then averaged over
10 seconds to control for artefacts. Blood pressure and HR were measured continuously via an
automatic sphygmomanometer and a 12-lead electrocardiogram (Ergospirometer Power-
Cube1-Ergo, Ganshorn Medizin Electronic, GER). The non-invasive anaerobic threshold was
defined by the HRTP. HRTP was demarcated as the intersection of two regression lines of
HRPC between post-warm-up and Pmax, determined from a second-degree polynomial repre-
sentation satisfying the condition of least error squares [8]. All measurements were conducted
at Profil, Neuss, Germany.
Statistical analyses
Data were tested for normal distribution via Shapiro-Wilk test. Descriptive statistics included
mean and standard deviation for participant’s characteristics. kHR was calculated by a second-
degree polynomial representation between post-warm up and Pmax. Stepwise linear regression
was used to explore relationships between kHR and diabetes markers (glycemic control
(HbA1c), total daily dose of insulin (both basal- and bolus insulin), duration of diabetes),
anthropometry (height, weight, body mass index (BMI)) and physical activity (IPAQ). Stepwise
linear regression was also used between kHR and exercise physiological markers (CPX derived
cardio-respiratory markers at HRTP and at Pmax). Stepwise linear regressions were adjusted for
gender, BMI, physical activity, total daily dose of insulin, duration of diabetes and blood glucose
concentration at the start of CPX testing if not included in the regression model. Logarithmic
transformation was performed if data were non-normally distributed. Receiver operating char-
acteristic (ROC) curves based on kHR for groups kHR < 0.20 vs.> 0.20 in relation to HbA1c. All
statistical analyses were carried out using SPSS V.22.0 statistical software (SPSS, Chicago, Illi-
nois, USA). A sample size of 64 individuals with T1DM resulted in a power (1 –β error proba-
bility) of 1.0 for the main outcome analyzed via stepwise linear regression, respectively.
Results
Relationships between kHR and HbA1c, total daily dose of insulin, duration
of diabetes, anthropometry and physical activity
We found significant relationships between kHR and HbA1c (β = -0.70, P< 0.0001), age
(β = -0.23, P = 0.03) and duration of diabetes (β = 0.20, P = 0.04) (Fig 3). Stepwise linear regres-
sion resulted in an overall adjusted R2 of 0.57 (R = 0.79, P< 0.0001).
Relationships between kHR exercise physiological markers
Our data revealed significant associations between kHR and percentage of HR at HRTP from
HRmax (β = 0.43, P< 0.0001) and Pmax relativized to bodyweight (β = 0.44, P = 0.001). Stepwise
linear regression resulted in an overall adjusted R2 of 0.44 (R = 0.53, P< 0.0001) (Fig 4).
CPX testing in individuals with type 1 diabetes
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ROC curve analysis based on kHR
ROC curve analysis based on kHR for groups kHR < 0.20 vs.> 0.20 resulted in a HbA1c thresh-
old of 7.9% (63 mmol.mol-1) (81% sensitivity and 82% specificity) (Fig 5).
Discussion
This study demonstrated the clear association between poor glycemic control and HR dynam-
ics during CPX testing. Intriguingly, higher HbA1c and its translation to atypical kHR resulted
in lower HR responses at the HRTP and lower bodyweight-relativized maximum power out-
put. Several physiological mechanisms might explain these novel findings:
Diabetes specific co-morbidities (e.g. structural myocardial alterations, ventricular and/or
arterial stiffness, impaired baroreflex sensitivity and cardiovascular autonomic neuropathy)
might minimally contribute to these alterations in kHR, as the cohort in our trial underwent
detailed physical examination [12,18].
Potentially the findings from our study are associated with impairments in ß1-adrenorecep-
tors. Poor glycaemic control is associated with chronically elevated catecholamine levels [19]
and can induce ß1-adrenoreceptor insensitivity. Impairment in ß1-adrenoreceptor sensitivity
is known to alter the ability of HR to respond adequately to increasing metabolic demands
[20]. ß1-adrenoreceptors produces positive inotropy, chronotropy and lusitropy with further
positive dromotropic effect and pacemaker activity from the sinoatrial node [21]. We hypothe-
size if ß1-adrenoreceptor insensitivity is present, a lower rise in free intracellular Ca
2+ concen-
tration dysregulates cardiac muscle contraction [22,23] resulting in CI during CPX testing.
Fig 3. Single plots of the association of kHR and HbA1c (A), age (B) and diabetes duration (C). kHR = degree and
direction of the heart rate to performance curve.
https://doi.org/10.1371/journal.pone.0194750.g003
Fig 4. Single plots of the association of kHR and HRHRTP at %HRmax (A) and Pmax (B). kHR = degree and direction of the
heart rate to performance curve, HRHRTP at %HRmax = heart rate at the heart rate turn point given as percentages of the
maximum heart rate, Pmax = maximum power output relativized to bodyweight.
https://doi.org/10.1371/journal.pone.0194750.g004
CPX testing in individuals with type 1 diabetes
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Taking this into account for our study cohort, we postulate that elevated HbA1c may modify
the typical HR response to stress via ß1-adrenoreceptor hyposensitivity.
Similar to the findings from our study, previous studies observed reduced cardiac output
during sub-maximal exercise intensities in individuals with T1DM [24][13]. Intriguingly, for
our data this was not only supported by the decreased ratio of HR at HRTP as percentage of
HRmax, we also found for the non-adjusted stepwise linear regression (data not shown) a sig-
nificant increased O2-Pulse (surrogate parameter for stroke volume) at the HRTP in individu-
als with poor glycaemic control. We postulate that the decreased ratio of HR at HRTP as
percentage of HRmax is compensated via increased stroke volume at the HRTP to maintain
adequate cardiac output in relation to metabolic demands.
Several studies found a decreased exercise performance in comparison of individuals with
T1DM and their healthy counterparts [25][26]. However, little research exists on its relation to
glycaemic control [13], and to the best of our knowledge, no trials investigated the influence of
CI on exercise performance. As found in our study, CI analyzed via kHR was associated with
lowered Pmax (W.kg
-1).
ROC curve clearly showed that HbA1c above 7.9% (63 mmol.mol
-1) was associated with
kHR towards CI in the transition of HRTP to Pmax. A low HbA1c accompanied with low risk of
hypoglycemic episodes are important aspects of the management of T1DM. However, the per-
centage of people with T1DM achieving HbA1c within 7.0% (53 mmol.mol
-1) and 7.5% (58
mmol.mol-1) is only from 8% to 28% [27–30] and it is unclear if such glycemic control targets
Fig 5. Receiver operating characteristic (ROC) curve analysis of HbA1c. The sensitivity is plotted against 100–
specificity to indicate accuracy. The optimal value for sensitivity was 81%, which corresponded to a specificity of 82%.
This represents a cut off level for HbA1c of 7.9% (63 mmol.mol
-1).
https://doi.org/10.1371/journal.pone.0194750.g005
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are attainable for most patients. It might be that more applicable HbA1c targets (potentially
supported by our threshold of 7.9% (63 mmol.mol-1)) accompanied with regular physical
activity and exercise could be more beneficial in reduction of risk of all-cause mortality and
cardiovascular disease [31] and eventually play a role in restoration of counter-regulatory
responses to hypoglycemia [32].
From a clinical point of view the findings from this study could be of immense interest for
an exact prescription of exercise intensity. The American Diabetes Association recommends at
least 150 min per week of moderate intensity aerobic physical activity, defined as percentages
of HRmax [33]. In consideration of the results from our study regarding HR at HRTP given as
percentages of HRmax, we might dissuade from using percentages of HRmax. Fixed percentages
of HRmax would lead to an overestimation of exercise intensity in individuals with poor glycae-
mic control as in these patients the anaerobic threshold (HRTP) was found in a lower percent-
age to HRmax.
This study is somewhat limited by possible differences in c-peptide status, which was not
measured for the purpose of this study. Further studies are needed to investigate kHR and ß1-
adrenoreceptor sensitivity in people with T1DM.
Conclusions
This is the first study, which found associations between kHR and HbA1c, age and duration
of diabetes in people with T1DM. Individuals with poor glycaemic control showed slower
increases in HR during early stages of CPX testing, which translated to (i) a decreased ratio of
HR at HRTP as percentage of HRmax and (ii) a lowered body weight-relativized Pmax. Age and
diabetes duration were also found to play a role for these findings. However, both factors con-
tributed minimally to the results (age: β = -0.23; diabetes duration: β = 0.20).
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